AGIO:NGS-Agios Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 42.65

Change

+0.63 (+1.50)%

Market Cap

USD 2.60B

Volume

0.31M

Analyst Target

USD 65.45
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.76 (+0.39%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-1.77 (-0.17%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-1.54 (-0.57%)

USD 34.86B
ARGX argenx NV ADR

-13.04 (-2.40%)

USD 32.89B
MRNA Moderna Inc

-0.87 (-1.42%)

USD 25.27B
BGNE BeiGene Ltd

+12.40 (+5.31%)

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

+5.86 (+1.67%)

USD 15.95B
SMMT Summit Therapeutics PLC

+0.48 (+2.58%)

USD 15.35B
PCVX Vaxcyte Inc

+0.21 (+0.19%)

USD 14.00B

ETFs Containing AGIO

WDNA 2.46 % 0.00 %

N/A

N/A
WBIO:LSE WisdomTree BioRevolution .. 2.45 % 0.00 %

-0.60 (0%)

USD 3.76M
WDNA:LSE WisdomTree BioRevolution .. 2.44 % 0.00 %

-0.02 (0%)

N/A
WRNA:XETRA WisdomTree BioRevolution .. 2.28 % 0.00 %

+0.04 (+0%)

USD 2.77M
AVSC American Century ETF Trus.. 0.35 % 0.00 %

+0.81 (+0%)

USD 1.34B
ETHO Amplify ETF Trust 0.00 % 0.45 %

+0.65 (+0%)

USD 0.18B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 91.51% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 91.51% 92% A 95% A
Trailing 12 Months  
Capital Gain 59.86% 88% B+ 92% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 59.86% 88% B+ 92% A
Trailing 5 Years  
Capital Gain -6.86% 71% C- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.86% 71% C- 44% F
Average Annual (5 Year Horizon)  
Capital Gain -4.95% 52% F 33% F
Dividend Return -4.95% 52% F 31% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 30.30% 84% B 61% D-
Risk Adjusted Return -16.34% 46% F 32% F
Market Capitalization 2.60B 91% A- 82% B

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.80 72% 93%
Price/Book Ratio 2.05 61% 46%
Price / Cash Flow Ratio -8.06 77% 81%
Price/Free Cash Flow Ratio -2.48 60% 70%
Management Effectiveness  
Return on Equity -39.61% 75% 36%
Return on Invested Capital -40.95% 64% 25%
Return on Assets -24.55% 65% 22%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector